SCHEMBL5133409

SCHEMBL5133409

Fc1cccc(-n2ncc3c(OC4CCNCC4)ncnc32)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 2/20 0.49
SLC2A3 P11169 2/20 0.49
SLC2A2 P11168 1/20 0.49
MAPT P10636 7/20 0.45
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 3/20 0.45
GSK3B P49841 2/20 0.44
GPR119 Q8TDV5 4/20 0.42
CYP17A1 P05093 1/20 0.41
CYP1A2 P05177 1/20 0.41
CHRM3 P20309 1/20 0.41
SLC6A2 P23975 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
LMNA P02545 3/20 0.41
TP53 P04637 3/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12835416 0.83 GPR119 (0.51) SLC2A1SLC2A3SLC2A2GPR119CYP17A1
SCHEMBL12835609 0.83 GPR119 (0.46) SLC2A1SLC2A3SLC2A2MAPTGPR119
SCHEMBL1243451 0.83 GPR119 (0.53) SLC2A1SLC2A3SLC2A2MAPTNPC1
SCHEMBL28776749 0.81 GPR119 (0.48) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL386438 0.79 GPR119 (0.70) GPR119TP53
SCHEMBL12904116 0.77 GPR119 (0.50) SLC2A1SLC2A3SLC2A2MAPTNPC1
SCHEMBL390767 0.76 GPR119 (0.68) GPR119
Hydrochloric Acid SCHEMBL1244784 0.76 GPR119 (0.67) GPR119
SCHEMBL5133985 0.75 GPR119 (0.48) MAPTNPC1RAB9AALDH1A1GPR119
SCHEMBL3155211 0.74 CHRM3 (0.70) CHRM3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2287166-A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto Arena Pharmaceuticals, Inc. (US) 2011-02-23 EP disclosed
EP-2287165-A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto Arena Pharmaceuticals, Inc. (US) 2011-02-23 EP disclosed
CN-101420941-A Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies ARENA PHARM INC (US) 2009-04-29 CN disclosed
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed